Titan Pharmaceuticals, Inc.

TTNP

US8883147055

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-17 EDT			5-day change	1st Jan Change
5.67 ^USD	+9.04%		+19.12%	-31.27%

07-02	Top Premarket Gainers	MT
05-15	Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Titan Retains Canaccord Genuity To Assist In Strategic And Financial Alternatives

January 22, 2018 at 12:00 am

Titan Pharmaceuticals, Inc. (NasdaqCM:TTNP) retained Canaccord Genuity Group Inc. (TSX:CF) to assist in this effort as part of an evaluation of strategic and financial alternatives. Titan and Braeburn Pharmaceuticals (BBRX) are in discussions regarding their partnership for the development and commercialization of Probuphine.

Latest news about Titan Pharmaceuticals, Inc.

Top Premarket Gainers	07-02	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Titan Pharmaceuticals Regains Compliance With Nasdaq Listing Rule	01-26	MT
Titan Pharmaceuticals, Inc. Announces Resignation of Brian Crowley as Senior Vice President, Finance and Administration, Effective February 2, 2024	01-18	CI
Titan Pharmaceuticals to Implement 1-for-20 Reverse Stock Split	12-29	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	23-10-16	CI
Titan Pharmaceuticals Appoints New Chairman of the Board	23-10-16	MT
Titan Pharmaceuticals, Inc. Announces Board Resignations	23-09-19	CI
Titan Pharmaceuticals, Inc. announced that it expects to receive $9.5 million in funding from Sire Group Ltd	23-09-12	CI
Fedson, Inc. completed the acquisition of Certain ProNeura Assets of Titan Pharmaceuticals, Inc..	23-08-31	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Fedson, Inc. entered into an Asset Purchase Agreement to acquire Certain ProNeura Assets of Titan Pharmaceuticals, Inc. for $52 million.	23-07-26	CI
Titan Pharmaceuticals, Inc. Announces Board Changes	23-07-07	CI
Insider Sell: Titan Pharmaceuticals	23-06-23	MT
Titan Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Titan Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Titan Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Sector Update: Health Care Stocks Sink on Thursday	22-12-15	MT
Sector Update: Health Care	22-12-15	MT
Titan Pharmaceuticals Signs Letter of Intent for Reverse Merger; Shares Drop	22-12-15	MT
Titan Pharmaceuticals, Inc. Appoints David E. Lazar as Chief Executive Officer, Effective August 16, 2022	22-12-15	CI
Titan Pharmaceuticals, Ocular Therapeutix Sign Licensing Agreement on Ophthalmic Patent Applications in US	22-12-12	MT
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc	22-12-12	CI

Chart Titan Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.

Sector

Pharmaceuticals

Calendar

2024-11-10 - Q3 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
TITAN PHARMACEUTICALS, INC.	-31.27%	4.75M
ELI LILLY AND COMPANY	+55.35%	848B
NOVO NORDISK A/S	+31.64%	627B
JOHNSON & JOHNSON	-0.10%	363B
MERCK & CO., INC.	+15.47%	318B
ABBVIE INC.	+13.10%	299B
ASTRAZENECA PLC	+15.51%	243B
NOVARTIS AG	+16.72%	225B
AMGEN INC.	+16.54%	179B
PFIZER, INC.	+4.31%	167B